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Abstract
Platelet-derived growth factor B (PDGF-B) overexpression induces gliomas of different grades from murine embry-
onic neural progenitors. For the first time, we formally demonstrated that PDGF-B–induced neoplasms undergo pro-
gression from nontumorigenic low-grade tumors toward highly malignant forms. This result, showing that PDGF-B
signaling alone is insufficient to confer malignancy to cells, entails the requirement for further molecular lesions in
this process. Our results indicate that one of these lesions is represented by the down-regulation of the oncosup-
pressor Btg2. By in vivo transplantation assays, we further demonstrate that fully progressed tumors are PDGF-B–
addicted because their tumor-propagating ability is lost when the PDGF-B transgene is silenced, whereas it is
promptly reacquired after its reactivation. We provide evidence that this oncogene addiction is not caused by the
need for PDGF-B as a mitogen but, rather, to the fact that PDGF-B is required to overcome cell-cell contact inhibition
and to confer in vivo infiltrating potential on tumor cells.
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Introduction
Gliomas are a heterogeneous group of almost incurable cancers. They
are classified according to their histopathologic features and to the ex-
pression of markers of different glial lineages, into astrocytomas, oligo-
dendrogliomas, mixed oligoastrocytomas and glioblastomas. The latter
is the most malignant form and is commonly regarded as the highest
grade of astrocytoma [1,2], although it has been recently proposed
that some glioblastomas may instead represent high-grade oligoden-
drogliomas [3]. The diversity of gliomas is mirrored by the number
of different signaling pathways shown to play roles in the generation
of these tumors [1,4,5].
A common molecular lesion found in gliomas of different histo-
pathological grades is the alteration of platelet-derived growth factor
B (PDGF-B) signaling [6–8]. The relevance of this signaling pathway
to the process of gliomagenesis has been demonstrated by studies in the
mouse, where both perinatal and adult progenitor/stem cells can be in-
duced to generate oligodendrogliomas, astrocytomas, and glioblastomas
by forced overexpression of PDGF-B [9–15]. Despite this wealth of
data, it is still unclear whether and how PDGF-B signaling contributes
to processes beyond tumor initiation, such as the acquisition and the
maintenance of progressively more malignant phenotypes.
In our work, we investigated these issues and demonstrated that
PDGF-B–induced tumors acquire malignant features, progressing
from low- to high-grade lesions, and that the down-regulation of the
oncosuppressor Btg2 is involved in this process. Furthermore, by loss-
and gain-of-function approaches, we show that continued PDGF-B
overexpression is necessary for the maintenance of the tumorigenic
activity of the fully progressed tumor cells, which therefore results
addicted to PDGF-B and never acquire independency from the initi-
ating stimulus.
Abbreviations: IRES, internal ribosome entry site; GFP, green fluorescent protein;
GFAP, glial fibrillary acidic protein
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Materials and Methods
Cell Cultures
Cultures from tumors were established microdissecting green fluo-
rescent protein (GFP)–positive areas under the fluorescence micro-
scope and trypsinizing them for 20 minutes. All tumor cultures were
maintained in DME-F12 added with B27 supplement and human
recombinant fibroblast growth factor 2 and epidermal growth factor
(20 ng/ml; Invitrogen, Carlsbad, CA) and plated on to Matrigel-
coated flasks (1:200; BD Biosciences, San Jose, CA). For immunohis-
tochemistry, cells were plated onto 13-mm-diameter coverslips coated
with poly-D-lysine and fixed in 4% paraformaldehyde 2 days after.
For growth curve analyses and focus formation assays, 105 cells
were plated within 35-mm-diameter Matrigel-coated wells and then
either counted after trypsinization at the indicated time points or
allowed to overgrow and be monitored for the presence of cell foci.
Each condition/time point was analyzed in triplicate cultures.
Fluorescent Activated Cell Sorting
Acutely dissociated and cultured tumor cells were sorted using a
FACSAria (BD Biosciences, Inc.). Purified GFP-positive and GFP-
negative cell populations were visually inspected after sorting under
a fluorescent microscope to quantify the contaminating fraction,
which was <1% in most cases analyzed.
Retroviral Vectors and Transduction Procedures
The cDNA of mouse PDGF-B, derived from the RCAS-pBIG
plasmid (kindly provided by Dr. E. Holland, Memorial Sloan-Kettering
Cancer Center, New York), was inserted into the SalI site of the pCEG
retroviral vector (kindly provided by Gordon Fishell, The Skirball In-
stitute of Biomolecular Medicine, New York) and into the blunted
PmeI/SfiI sites of the pCAG:Ds-Red vector (kindly provided by
Dr. M. Goetz, Institute of Stem Cell Research, Germany), upstream
the internal ribosome entry site (IRES)–Ds-Red reporter cassette. All
the PDGF-B overexpression experiments, in vitro and in vivo, were car-
ried out using the IRES-containing retroviral vector, inwhich the coding
sequences for GFP or Ds-Red were downstream the IRES. Control
experiments were performed using the retroviral vectors coding the re-
porters alone or the β-glucuronidase gene (GUS).
Replication-defective retroviral supernatants were prepared by
transiently transfecting plasmids into Phoenix packaging cells as de-
scribed elsewhere [16]. Retroviral vectors where used on cultured
cells as previously described in the study of Heins et al. [17] and
in vivo as described in the study of Appolloni et al. [18].
Animal Procedures
Mice were handled in agreement with the guidelines conforming
to the Italian current regulations regarding the protection of animals
used for scientific purposes (D.lvo 27/01/1992, n. 116). Procedures
were specifically approved by the Ethical Committee for Animal
Experimentation of the National Institute of Cancer Research and
by the Italian Ministry of Health. All experiments have been per-
formed on the C57/Bl6 mouse strain.
In utero intraventricular injections were performed as described
elsewhere [19]. Animals injected at embryonic stages were let develop
to term, and after birth, they were monitored for the appearance of
symptoms indicating the presence of brain tumors. At first signs of
symptoms, the animals were killed and perfused with 4% parafor-
maldehyde. The brains were photographed on a transilluminator
and/or cryoprotected in 20% sucrose and sectioned with a Leica
CM1100 cryostat (Wetzlar, Germany).
Tumor cells were injected in deeply anesthetized adult animals
mounted on a stereotaxic apparatus. Up to 5 μl of cell suspension
for each mouse, containing 50 to 50,000 cells, were injected using a
Hamilton syringe (Bregma coordinates: AP, 1.0 mm; L, 1.5 mm left
and 2.5 mm below the skull surface). Reabsorbable suture was used
before awakening the animals. Animals were then monitored daily
for the onset of neurologic symptoms.
Immunostaining
Immumostainings on brain sections or cultured cells were per-
formed using the following antibodies: mouse monoclonal antibodies
against Nestin (1:250; BD Pharmingen, San Diego, CA); glial fibril-
lary acidic protein (GFAP, 1:200; Sigma, St. Louis, MO), adenoma-
tous polyposis coli (APC, 1:100, CC1; Calbiochem, San Diego, CA),
BrdU (1:50; Bio-science Products AG, Emmenbruecke, Switzerland);
rabbit polyclonal antibodies against Olig2 (1:200; Sigma), Ng2 (1:300;
Chemicon-Millipore, Billerica, MA), and Sox2 (1:500; Chemicon-
Millipore); chicken polyclonal antisera against GFP (1:500; Abcam,
Cambridge, United Kingdom); and rat monoclonal antibodies against
PDGFRα (1:100; BD Pharmingen) and Ki67 (1:25, tec3 clone;
Dako, Glostrup, Denmark). Binding of primary antibodies was re-
vealed with appropriate secondary fluorescein isothiocyanate– and tet-
ramethyl rhodamine isothiocyanate–conjugated antibodies (1:50;
Immucor, Norcross, GA) or biotinylated secondary antibodies (1:50;
Dako), which were revealed with streptavidin-conjugated Alexa 488
(1:500; Molecular Probes-Invitrogen). Nuclei were stained through
5 minutes of incubation in DAPI solution (1 μg/ml; Sigma).
Immunostainings were examined with an Eclipse 800i (Nikon,
Tokyo, Japan). Images were acquired with Nikon Digitalsight DS-
M5c camera and analyzed with ImageJ (W.S. Rasband, ImageJ, US
National Institutes of Health, Bethesda, MD; http://rsb.info.nih.
gov/ij/, 1997-2007).
Data Analysis on Brain Sections and Cultured Cells
The means and SEs were calculated from different experiments.
“n” denotes the number of animal used for in vivo experiments.
The threshold for statistical significance, which was determined with
a 2-tailed Student’s t test, was considered as P < .05.
Real-time Polymerase Chain Reaction
Genomic DNA from sorted GFP-positive and GFP-negative cells
was obtained by lyising the cells in 100 mM Tris-Cl pH 8.5, 5 mM
EDTA, 0.2% SDS, 200 mM NaCl, and 100 μg/ml proteinase K at
56°C and precipitated with isopropanol. In other cases, RNA was ex-
tracted from sorted cells from primary tumors or cultures with TRIzol
reagent (Invitrogen) according to the manufacturer’s guidelines.
cDNA was then obtained from 500 ng of RNA using the iScript
(Bio-Rad Laboratories, Hercules, CA) retrotranscription kit. Quan-
titative real-time polymerase chain reaction (PCR) was performed
on 10 ng of genomic sample or 1:100 of the retrotranscription reaction
using iQ SYBRGreen Supermix (Bio-Rad Laboratories). The presence
of the proviral insert was determined using a pair of primers specific for
GFP amplification, whereas the amplification level of the Fyn gene
(MGI:95602) was used as reference for data normalization because
it has no pseudogenes. mRNA quantifications were normalized to
the housekeeping gene Rpl41 (NM_018860). The sequences of the
primers are available on request.
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Results
Transduction of PDGF-B in Embryonic Precursors Provokes
Tumors Resembling Oligodendrogliomas
We injected replication-deficient retroviruses carrying both PDGF-
B– and GFP-coding sequences into the lateral ventricles of the telen-
cephalon in mouse embryos at mid neurogenesis (embryonic day 14;
E14). After birth, the injected mice were monitored and killed as
soon as they showed symptoms of neurologic distress, which ap-
peared in all injected animals within 190 days (n = 46; Figure 1A).
In contrast, no mice ever developed gliomas when injected with a con-
trol virus (n = 15). The analysis of the brains explanted from PDGF-
B–injected animals showed, invariably, masses of GFP-positive cells,
indicating a large proliferation of cells that had integrated the PDGF-
B–expressing retrovirus (Figure 1B).
A more accurate analysis of the survival curve showed that mice
developed symptoms with different latency, roughly classifiable in
two groups: early-affected and late-affected mice (Figure 1A). Early-
affected mice often displayed hydrocephaly and weight loss within 2
to 8 weeks after birth with an average of 37 ± 2 days. In most cases, the
severe hydrocephalic condition was the likely cause of the symptoms.
On histologic analysis, these brains showed broad infiltration of GFP-
positive cells within an average volume of 7 ± 4 mm3, without display-
ing the typical signs of high-grade gliomas, such as widespread necrosis
or massive neovascularization (Figure 1, C , E , and E ′), and for this
reason, we herein refer to these cellular hyperplasias as low-grade tumors.
In contrast, the late-affected animals exhibited symptoms, ranging
from hyperreactivity to imbalanced stance and gait, within 70 to
190 days after birth with an average of 136 ± 13 days, and developed
large GFP-positive tumor masses, with an average volume of 65 ±
10 mm3, without showing hydrocephalous. Most of these brains
(15/16) showed wide hemorrhagic regions, were extensively infiltrated,
and harbored wide and highly cellularized areas, with clear necrotic
regions surrounded by pseudopalisades and newly formed blood vessels
(Figures 1,D, F, and F′ andW1), all typical signs of high-grade gliomas
[1]. In some cases, the tumor mass had completely invaded and almost
replaced normal tissues in areas such as the ventral telencephalon and
the thalamus (Figure 1D).
Owing to the striking difference in the volume of the infiltrated
regions (about an order of magnitude), low- and high-grade tumors
can be readily distinguished by a macroscopic inspection of the brain
on a blue light transilluminator allowing visualization of the GFP.
The presence of hemorrhagic regions within the GFP-positive areas
could be used as an additional macroscopic criterion to identify high-
grade tumors.
Immunohistochemical analysis showed that transduced cells in
low- and high-grade tumors did not express either astroglial or neu-
ronal markers, being devoid of GFAP and NeuN (Figure 2, A, B,
I , and J ). Transduced cells expressed the proliferative marker Ki67
(Figure 2, C and K ) and progenitor/stem cells markers such as the
intermediate filament Nestin [20], suggesting that they were not fully
differentiated (Figure 2, D and L). They also widely expressed oligo-
dendrocyte lineage–specific markers such as the bHLH transcription
factor Olig2 [21] (Figure 2, E and M ), the proteoglycan NG2 [22]
(Figure 2, F and N ), the PDGFRα (Figure 2, G and O), and the
form of the APC gene product recognized by the CC1 antibody
[23] (Figure 2, H and P).
This analysis shows that the tumors generated by embryonic trans-
duction of PDGF-B are composed of cells showing unambiguous
traits of the oligodendroglial lineage, suggesting that they all represent
different grades of oligodendrogliomas and corroborating the notion
that some glioblastomas with oligodendroglial component could in-
deed represent “grade IV oligodendroglioma” [3].
Only High-grade Tumors Induced by PDGF-B Are
Tumorigenic When Transplanted
Platelet-derived growth factor B–transduced cells in both high-
and low-grade tumors showed high proliferation activity (Figure 2,
C and K ), as demonstrated by the percentage of Ki67-positive cells,
approximately 20%, among the transduced population [24]. How-
ever, we noticed that high-grade tumors, identified through macro-
scopic inspection as described previously, gave rise in extremely short
times to secondary gliomas in 73% of intracranially transplanted
adult animals (38 ± 9 days; n = 15 from six independent primary
tumors), whereas low-grade tumors, despite a similar expression profile
and proliferative activity, failed to cause any sign of illness following
Figure 1. PDGF-B–induced brain tumors with high efficiency. (A)
Survival curve (black line) and average death rate plot (dead animal
per day, red line) for primary tumors induced by PDGF-B overex-
pression. (B) Merged fluorescence and brightfield images of a typ-
ical high-grade primary tumor. (C–F′) Coronal sections of primary
low-grade (C, E, and E′) and high-grade (D, F, and F′) tumors stained
with anti-GFP antibody in green (C, E′, D, and F′) or hematoxylin and
eosin (E and F). Corresponding fluorescence and bright field micro-
photographs (E–E′ and F–F′) were taken from the same sections
after each staining step. Scale bars, 1 mm (B–D); 100 μm (E–F′).
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the same experimental paradigm (n = 13 from five independent pri-
mary tumors; Figure 3A). The secondary tumors generated by intra-
cranial transplantation of high-grade glioma cells resembled their
parental counterparts, but they displayed a more compact structure,
surrounded by reactive astrocytes (Figure 3B), whereas primary tumors
typically harbored also a cellular fraction extensively infiltrating the
surrounding brain regions. Like their high-grade primary sources, sec-
ondary tumors were extremely vascularized and showed wide necrotic
areas surrounded by highly proliferating cells forming pseudopalisades
(data not shown).
To further evaluate the ability of the tumorigenic component to self-
renew during long periods, we serially transplanted secondary tumors
into the brain of adult mice. This resulted in the generation of tertiary
tumors that showed no obvious difference to their secondary sources
in the symptoms onset and proliferative index (data not shown).
High-grade Tumors Can Be Grown in Culture During Long
Periods Maintaining Their Tumorigenic Potential and
Molecular Phenotype
The difference between low- and high-grade tumors was also re-
flected by their different abilities to be propagated in culture. Approx-
imately 80% (n = 12) of high-grade tumors, identified by macroscopic
inspection, were successfully maintained in vitro after dissociation,
whereas dissociated cells from low-grade tumors (n = 12) invariably
tended to differentiate and eventually die within a few days after plating.
High-grade tumors were cultured efficiently for more than 20 passages,
without any obvious change in their morphology and proliferative
potential. Similarly to their in vivo tumor counterparts, cultured cells
from high-grade tumors almost never expressed the astrocytic marker
GFAP, whereas they were immunopositive for oligodendroglial markers
such as Olig2, APC, and NG2 and for the immature neural progenitor
marker Nestin (Table W1 and Figure 3C ).
When cultured cells from independent high-grade tumors were
tested for their tumorigenic potential by intracranial reinjections,
they all gave rise to secondary tumors, with an average efficiency
of 87 ± 9% (five independent tumors, n ≥ 3 injected mice per tumor;
Figure 3A). Secondary tumors displayed similar histopathology and
latency (on average, 39 ± 3 days) compared to those generated when
reinjecting acutely dissociated cells from high-grade tumors.
A gross estimation of the proportion of tumor-initiating cells within
the culture of one representative tumor was obtained by applying the
Spearman-Kärber formula [25] to the results of a serial logarithmic
dilution/transplantation assay, and it revealed that transplantation of
Figure 2. PDGF-B overexpression induced tumor resembling oligodendrogliomas. (A–P) Immunofluorescence stainings of low- (A–H)
and high-grade (I–P) tumor sections with anti-GFP antibody in green, DAPI for nuclear staining in blue, and the antibody for the indicated
antigen in red. (K, dashed contour) A pseudopalisading structure in a high-grade tumor is shown. Scale bars, 50 μm.
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as few as 140 cells would cause a tumor in half of the animals (i.e.,
DL50 = 140; n = 12 animals, four dilutions).
These data indicate that high- and low-grade PDGF-B–induced
oligodendrogliomas, despite the similarities at the immunohisto-
chemical and proliferative levels, differ markedly in that only high-
grade tumors are able to self-renew extensively in vivo and in vitro,
giving rise to new high-grade gliomas in short times. Altogether,
these observations demonstrate that PDGF-B overexpression is alone
Figure 3. High-grade tumors are tumorigenic and can be propagated in culture. (A) Survival curves for animals transplanted with cells from
low-grade (blue line) or high-grade (red line) acutely dissociated primary tumors and cultured high-grade tumor cells (green dotted line). (B)
Fluorescence microphotograph of a coronal section of a secondary tumor (green) showing encapsulation by GFAP-expressing astrocytes
(anti-GFAP antibody in red). (C) Immunofluorescence stainings of cultured cells from PDGF-B–induced tumors with anti-GFP (green) anti-
body, DAPI for nuclear staining (blue), and antibodies for the indicated neural lineage markers (red). Scale bars, 1 mm (B); 25 μm (C). (D)
Alternative scenarios for the acquisition ofmalignancy during PDGF-B–induced gliomagenesis. Tumorigenic potentialmay be either acquired
by progression (upper panel) or possessed from the onset (lower panel). (E) Design of the experiments for testing the proposed hypotheses
by challenging the ability to generate secondary tumors of cells derived from randomly sorted pups injected with PDGF-B retrovirus.
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insufficient to provide glial progenitors with a full-blown tumorigenic
potential, as shown by the lack of such character in low-grade PDGF-
B–expressing tumors, hence suggesting that PDGF-B–induced tu-
mors may follow a progression path culminating in the generation
of extremely aggressive forms. Alternatively, the two forms of tumor
might reflect an early difference, produced at the time of the infection.
PDGF-B–Induced Gliomas Progress from Low to High Grade
To distinguish between the two alternatives, we asked if the tumors
fated to show high-grade characteristics possess the capability of gen-
erating secondary tumors already at early times (i.e., when the low-
grade ones become symptomatic) or if they acquire this ability only
later by progression (Figure 3D). Ideally, addressing this question
would require the analysis of the tumorigenic potential of cells derived
from a series of early stage tumors and the ability to follow the devel-
opment of the very same tumors in the animals from which they have
been explanted. This strategy would imply the ability to resect part of
an early tumor, broadly infiltrated in the brain parenchyma, allowing
the animal to survive for one or two additional months. Although this
approach would formally allow assessing whether tumors that later will
showmalignant features are already tumorigenic at early stages, it is not
feasible in the mouse. However, we reasoned that it could be adapted
by taking advantage of inferential statistics.
From our experiments, we knew that high-grade tumors arise in ap-
proximately 40% of mice injected with PDGF-B at embryonic stages.
We therefore randomly sorted the pups of eight independent litters
injected with PDGF-B viruses defining two similarly sized pools (n =
13 and n = 14 mice), which were used as a source of cells (“reinjection
pool”) and as a reference (“control pool”), respectively (Figure 3E).
The control pool was left untouched, and the animals were killed
at the onset of the first symptoms, annotating the latency and the his-
topathology of the tumors. All the members of the reinjection pool
were killed approximately 30 days after birth (29 ± 3 days), around
the mortality peak of low-grade tumors, and the GFP-positive regions
found in their brains were dissected. At the time of the sacrifice, only
5 of 13 (approximately 40%) mice already displayed symptoms, but
tumor masses were present in all the brains. These masses appeared
similar in size and distribution, and all yielded several thousand
GFP-positive cells when dissociated. Six independent injections (n =
78) were then performed for every tumor (n = 13), using 1 ± 0.3 ×
104 GFP-positive cells per injection. Notably, the number of trans-
planted cells in this experiment was about two orders of magnitude
higher than the median lethal dose derived from experiments using
the cultured cells (i.e., 140 cells; see previous paragraphs). Thus, if
some GFP-positive mass harbored already tumorigenic cells, we would
expect them to give rise to secondary tumors in a very short time, sim-
ilar to the reinjection of late-onset high-grade tumors.
None of the animals receiving GFP-positive cells developed any tu-
mor, regardless of whether the donors were symptomatic or not. This
was in striking contrast with the ability of late-onset high-grade
PDGF-B–induced gliomas to give rise to secondary tumors with high
efficiency even after injection of only a few hundred cells. In contrast,
approximately 50% of the control pool displayed high-grade histo-
pathology and late onset. Assuming the percentage of tumors destined
to become high-grade gliomas to be approximately the same in the two
pools, we expected approximately seven mice within the reinjection
pool to be fated to develop a high-grade tumor. This observation dem-
onstrates that, at early stages, the tumors induced by PDGF-B over-
expression are equivalent, lacking the potential to generate secondary
tumors. The malignancy shown by late-onset tumors is therefore a
peculiar property acquired by progression.
A preliminary analysis aimed at identifying possible gene expression
alterations responsible for the progression was carried out by compar-
ing the expression levels of a limited number of candidate genes in
low- and high-grade tumors by real-time PCR. This analysis leads to
the identification of the gene Btg2, whose expression is significantly
lower in high-grade PDGF-B–induced gliomas compared to low-grade
ones (Figure 4A). These data show a strong correlation between the
acquisition of tumorigenic potential by PDGF-B–induced gliomas
and the down-regulation of Btg2, which may play a role as a tumor
suppressor in this context. In agreement with this possibility, Btg2 acts
as an oncosuppressor in medulloblastoma, another central nervous
system tumor [26], and its deregulation has been suggested to cooper-
ate with PDGF-B in driving the formation of gliomas [27,28].
Fully Progressed Tumor Cells Are Addicted to PDGF-B
Inspection of high-grade tumor cultures revealed the presence of a
substantial population of GFP-negative cells, which showed a marker
expression profile similar to that of GFP-positive cells (Table W1).
Notably, GFP-negative cells were able to proliferate extensively in
culture also in the absence of the PDGF-B paracrine support from
the GFP-positive fraction, after FACS purification, suggesting they
underwent the same progression pathway as the GFP-positive cells.
Accordingly, the level of Btg2 mRNA in GFP-negative cultures was
similar to the level of their PDGF-B/GFP-positive counterparts and
to acutely dissociated high-grade tumors (Figure 4A).
The similarity between GFP-positive and -negative cells, together
with the observation that GFP-positive clones obtained by multiple
dilutions generate a fraction of GFP-negative cells (data not shown),
prompted us to clarify if the GFP-negative population represents re-
cruited cells or if it derives from GFP-positive cells by silencing of the
proviral promoter. We therefore performed a real-time PCR analysis
to evaluate the presence of the integrated provirus into the genome of
the sorted GFP-negative cells. Our analysis showed that both GFP-
positive and -negative cells contain the same amount of provirus in
their genomes (Figure 4B), strongly supporting the hypothesis of the
provirus transcriptional silencing.
Despite their similarities, cultured GFP-positive and GFP-negative
cells dramatically differed in their ability to give rise to new tumors
when challenged with in vivo reinjections experiments. Cultured
GFP-positive cells from all tumors tested were able to give rise to
secondary gliomas with an average efficiency of 78 ± 15% (n = 18;
Figure 4C ). On the contrary, the GFP-negative fraction invariably
failed to do so even after injecting as many as 50,000 cells (more than
two orders of magnitude more than the estimated DL50 for GFP-
positive cells, see previous paragraphs; n = 12, Figure 4C ). These re-
sults, together with the observation that the GFP-negative fraction
derives from GFP-positive cells, strongly suggest that high-grade gli-
oma cells, although progressed to a highly malignant state, had not
become independent from PDGF-B signaling for their ability to
propagate as tumors in vivo. To further confirm that tumorigenic
potential depends on PDGF-B overexpression, we reinjected adult
mouse brains with cultured GFP-negative cells 2 days after their
transduction with a retroviral vector expressing PDGF-B in asso-
ciation with the red fluorescent protein Ds-Red. These cells proved
able to induce the formation of secondary gliomas with the same
efficiency of the GFP-positive counterpart, demonstrating that the
observed differences in tumorigenic potential between GFP-positive
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and GFP-negative cells could be entirely accounted for by the silenc-
ing of PDGF-B expression (Figure 4, C and D). The prompt loss of
tumorigenic potential on transgene inactivation demonstrates that
high-grade PDGF-B–induced gliomas are addicted to their triggering
oncogenic stimulus, despite the progression they have undergone.
Cellular Mechanisms Underlying PDGF-B Addiction
Having established that PDGF-B–induced high-grade gliomas
strictly depend on PDGF-B overexpression for maintaining their po-
tential to form tumors in vivo, we went on to investigate the cellular
mechanisms underlying this phenomenon.
As previously mentioned, cells that have lost PDGF-B overexpres-
sion by proviral silencing can be cultured and expanded without the
paracrine support of the PDGF-B–overexpressing cells and in the ab-
sence of added growth factors (data not shown). This indicates that
PDGF-B overexpression is dispensable for the in vitro proliferation of
cells deriving from these gliomas, revealing that cells that have pro-
gressed to malignancy are independent from the triggering oncogenic
stimulus for their ability to proliferate in culture. This also indicates
that the dependency on PDGF-B overexpression for the in vivo tumori-
genic potential (oncogene addiction) may not reside in a requirement
for PDGF-B as a mitogenic stimulus. To evaluate if and to which extent
the expression of PDGF-B may influence the proliferative potential of
glioma cells, we performed growth curve analyses on cultures of GFP-
positive and GFP-negative cells established from two independent
primary high-grade tumors. The analyses confirmed the ability of both
Figure 4. Btg2 is down-regulated in high-grade tumors that are addicted to PDGF-B. (A) Histogram shows the levels of Btg2 mRNA
as percentage of the level of the housekeeping gene Rpl41 in FACS-purified cells from primary tumors or cultured cells as indicated.
Values represent the means of real-time PCR quantifications for three independent tumors per condition. (B) Histogram shows the
amount of the integrated provirus in the genome of transduced GFP-positive and GFP-negative cells normalized to the amount of
the Fyn locus. (C) Survival curves for transplantation experiments using cultures of sorted GFP/PDGF-B–positive cells and of silenced
(GFP-negative) cells either untreated or reinfected with a PDGF-B–expressing or control virus. (D) Merged fluorescence and bright-
field photographs of a secondary tumor induced by silenced cells upon transduction with a PDGF-B/Ds-Red–expressing vector. Scale
bar, 2 mm.
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cell populations to proliferate extensively before reaching confluence, as
also shown by their similar percentage of cells incorporating BrdU dur-
ing a 24-hour pulse: 75 ± 5% (number of cells = 1967) for the GFP-
positive and 78 ± 5% (number of cells = 2794) for the GFP-negative
cells. However, a striking difference between these cell populations
became evident after reaching confluence, wherein PDGF-B–expressing
cells grew exponentially for at least 24 additional hours, whereas
the silenced population showed a sharp decrease in its growth rate
(Figure 5A). Most remarkably, PDGF-B–overexpressing cells eventually
formed massive foci, whereas GFP-negative (PDGF-B–silenced) cells
invariably failed to do so (Figure 5, B and C). Importantly, the reintro-
duction of PDGF-B by using a Ds-Red–encoding retrovirus in the
GFP-negative cells reestablished their ability to undergo unconstrained
cell proliferation, eventually resulting in the formation of foci (Figure 5,
A, D, and E).
Altogether, these data demonstrate that PDGF-B overexpression
allows cells to overcome the cell-cell contact–mediated inhibition of
proliferation and eventually display the ability to form foci, a property
often correlating with the tumorigenic potential of transformed cells.
Along with the ability to overcome contact inhibition of prolifer-
ation, malignant cells typically show the propensity to infiltrate sur-
rounding tissues. This is particularly true for gliomas that are almost
untreatable also owing to their marked tendency to infiltrate the
brain parenchyma. We therefore tested if PDGF-B overexpression
may correlate with the ability of cells to infiltrate the brain. Platelet-
derived growth factor B–overexpressing cells (number of cells = 1500)
were cotransplanted into adult mouse brains (n = 7) together with
PDGF-B–silenced cells labeled with a control retroviral vector coding
for Ds-Red (number of cells = 3500). We then killed two animals at
both 1 and 2 weeks after transplantation and allowed the others to de-
velop tumors before killing them. Sections from 1- and 2-week-old
brains revealed needle tracks containing weakly autofluorescent densely
packed cells. At 1 week after injection, both GFP-positive and Ds-Red–
positive cells were clearly visible around the needle track of all the brains
examined (n = 2; Figure 5F); however, unsurprisingly, their number was
much lower than that of injected cells. A striking observation was that,
whereas the distribution of Ds-Red-expressing cells was limited to the
needle track, the PDGF-B–overexpressing cells were found mostly out-
side the track and as far as in the contralateral hemisphere (data not
shown). Twoweeks after injection, the only detectable transplanted cells
were Ds-Red–positive and they were confined to the needle track. Im-
portantly, no GFP-positive cells were visible either inside or near the
injection site, suggesting that the few surviving cells had scattered in a
larger volume. All the remaining animals were killed after another 30 to
50 days because of the development of gliomas that were found to be
exclusively GFP-positive. These observations show that only a minority
Figure 5. (A) Representative growth curves of cultured high-grade tumor cells either expressing PDGF-B or not. (B–E) Fluorescence
microphotographs of cultured cells at confluence showing the focus formation: PDGF-B/GFP–expressing cells (B), PDGF-B–silenced
cells (C), PDGF-B–silenced cells reinfected with a Ds-Red control virus (D), PDGF-B–silenced cells reinfected with a PDGF-B/Ds-Red virus
(E). (F) Coronal section at the injection site 1 week after transplantation showing PDGF-B/GFP–positive cells (green, arrowheads) and
PDGF-B–silenced cells infectedwith a Ds-Red control virus (red, arrows); dashed lines indicate the limit of the needle track. Scale bar, 50 μm.
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of tumor cells survive the graft and, most importantly, that PDGF-B
overexpression and tumorigenic potential correlate with the in vivo
ability of glioma cells to scatter through the surrounding brain paren-
chyma. Indeed, silenced cells lack both the ability to infiltrate the sur-
rounding tissues and to form tumors upon transplantation. The rapid
decrease in the number of injected cells and the fast dispersal of theGFP-
positive cells through the brain that we observed in the first 2 weeks after
injection are likely the reasons why the PDGF-B expressed from the
GFP-positive cells failed to paracrinally support the growth and/or the
survival of the Ds-Red-expressing cells. This therefore explains why
the tumors resulting from the cotransplantations did not contain a
Ds-Red–positive component.
Discussion
In our attempt to characterize a model of gliomagenesis, we have
found that PDGF-B overexpression in telencephalic mouse neural
progenitor cells is highly efficient at inducing tumors. These tumors
comprise low- and high-grade forms, all sharing markers of the oligo-
dendroglial lineage, even when displaying histopathologic traits typi-
cal of glioblastoma, such as extended necrosis, pseudopalisades, and
widespread angiogenesis. This observation indirectly supports the
notion that some of the tumors named “glioblastomas with oligo-
dendroglioma component” in the last revision of the World Health
Organization classificatory scheme [3] could indeed be considered as
“grade IV oligodendroglioma.”
Tumors induced by embryonic transduction of PDGF-B comprised
a subgroup that was lethal within a few weeks after birth. Despite this
very aggressive behavior, early neoplasias possessed histopathologic
and functional properties that unambiguously allowed their classifica-
tion as low-grade tumors. Most prominently, these gliomas, which
could not be maintained in culture, were devoid of any sizable tumor-
initiating subpopulation, as demonstrated by our in vivo transplantation
experiments. Early tumors were completely unable to propagate them-
selves when reinjected intracranially, even when a high number of cells
were transplanted.
A relevant proportion of the PDGF-B–induced gliomas, character-
ized by longer latency, emerged as histopathologically and function-
ally highly malignant forms, ultimately causing the death of all
injected animals within a few months after birth. These forms could
be efficiently propagated in vivo in serial transplantation assays and
showed the potential for long-term in vitro culturing with no altera-
tion in their tumorigenic potential, as demonstrated by highly suc-
cessful intracranial reinjections using cultured tumor cells.
We used an inferential statistics approach to demonstrate that high-
grade tumors derive from nontumorigenic cells that, only later, acquire
tumorigenic potential. This shows that PDGF-B is able to drive the
formation of low-grade tumors that need to acquire further lesions
to progress toward malignancy. This experimental paradigm repre-
sents, therefore, an in vivo model of glioma progression.
As a possible candidate responsible for the observed progression,
we identified Btg2, which is strongly down-regulated in high-grade
tumors compared to low-grade ones. Btg2 is an interesting candidate
because it has been suggested to cooperate with PDGF-B overexpres-
sion in driving the formation of gliomas [27] and because it acts as an
oncosuppressor in medulloblastoma [26].
Our data show that, at least in this context, neither the overexpres-
sion of PDGF-B nor the down-regulation of Btg2 are alone sufficient
for a cell to be tumorigenic. This is demonstrated by the lack of malig-
nancy of both PDGF-B–overexpressing low-grade tumors and PDGF-
B–silenced high-grade tumor cells (that show a low level of Btg2). Rather,
tumorigenicity is a characteristic exhibited by cells displaying, at the same
time, PDGF-B overexpression and low Btg2 level. Altogether, these ob-
servations suggest that Btg2 may represent a relevant tumor suppressor
in the context of PDGF-B–induced gliomagenesis and that its down-
regulation is an important step during tumor progression.
Our observation that cells silencing the proviral expression of
PDGF-B impairs tumorigenic potential shows that PDGF-B overex-
pression, albeit alone insufficient to confer malignancy, is necessary
for the maintenance of this feature in high-grade tumors. Such onco-
gene addiction [29] was further confirmed by the reintroduction, into
silenced cells, of a new PDGF-B–expressing vector, which rescued
their tumor-propagating ability. Although other authors already
showed that the development of PDGF-B induced tumors is depen-
dent on continuous PDGF-B signaling [30,31], our data represent the
first demonstration that fully progressed tumors remain addicted to
their triggering oncogenic stimulus. If this is lost, cells completely lose
the ability to generate secondary tumors. As soon as it is restored, cells
reacquire full tumorigenic potential.
Cells undergoing proviral silencing, while losing the ability to prop-
agate as tumors in vivo, maintained a very similar molecular phenotype
and a very high proliferative potential in vitro. These observations
show, on the one hand, that during progression from low- to high-
grade tumors, cells must have accumulated additional alterations al-
lowing them to proliferate abnormally and, on the other, that the
in vitro proliferative activity does not necessarily correlate with the abil-
ity to regenerate a glioma on transplantation in vivo. Remarkably, we
found that the ability to overcome cell-cell contact–mediated growth-
inhibitory stimuli correlated with the tumorigenic potential of these
cells.We indeed demonstrate that PDGF-B overexpression plays a cru-
cial role in this process. Platelet-derived growth factor B–overexpressing
cells were not sensitive to growth-inhibitory stimuli induced by cell-cell
contacts and eventually formed foci, whereas silenced cells lacked the
ability to grow past confluence and reacquired it as soon as PDGF-B
overexpression was reestablished.
Altogether, our data demonstrate that PDGF-B overexpression
supports the formation and progression of oligodendrogliomas toward
highly malignant forms. We also show that cells from fully progressed
tumors remain dependent on PDGF-B overexpression for their tumor-
igenic potential. Our data suggest that the addiction to PDGF-B might
be connected to its requirement for suppressing cell-cell contact growth-
inhibitory signals.Moreover, our observations suggest a role for PDGF-B
in the invasive capability of glioma cells, showing that the PDGF-B over-
expression confers cells the ability to infiltrate the surrounding tissues.
Our data support the concept that, even in patients bearing highly
malignant tumors that have accumulated multiple molecular lesions,
therapies targeting a prominent oncogene may prove effective for lim-
iting tumor growth and relapse.
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Table W1. Neural Marker Expression in Cultured Tumor Cells.
Marker Cultured Tumor Cells
(a) GFP-Positive (b) GFP-Negative
GFAP ≪1% (850) ≪1% (900)
Olig2 94 ± 3% (687) 58 ± 14% (774)
APC(cc1) 66 ± 17% (948) 68 ± 18% (1702)
Ng2 92 ± 5% (808) 69 ± 6% (1080)
Nestin 95 ± 2% (849) 70 ± 9% (1472)
The percentage of positivity to the indicated molecular markers ± SE is indicated for both GFP-
positive and GFP-negative cultured tumor cells. Data were collected by three independent experi-
ments. In parentheses are indicated the total number of cells counted.
Figure W1. High-grade tumors harbor an aberrant blood vessel network. (A, B) Immunofluorescence staining with antibodies against
GFP in green (A, B) and phosphoVEGFR2 in red (A). (C) Hematoxylin and eosin staining of the same section as in (B). Scale bars, 50 μm.
